On the inflammatory response in metal-on-metal implants by Ulrike Dapunt et al.
Dapunt et al. Journal of Translational Medicine 2014, 12:74
http://www.translational-medicine.com/content/12/1/74RESEARCH Open AccessOn the inflammatory response in metal-on-metal
implants
Ulrike Dapunt1*, Thomas Giese2, Felix Lasitschka3, Jörn Reinders1, Burkhard Lehner1, Jan Philippe Kretzer1,
Volker Ewerbeck1 and Gertrud Maria Hänsch2Abstract
Background: Metal-on-metal implants are a special form of hip endoprostheses that despite many advantages can
entail serious complications due to release of wear particles from the implanted material. Metal wear particles
presumably activate local host defence mechanisms, which causes a persistent inflammatory response with
destruction of bone followed by a loosening of the implant. To better characterize this inflammatory response
and to link inflammation to bone degradation, the local generation of proinflammatory and osteoclast-inducing
cytokines was analysed, as was systemic T cell activation.
Methods: By quantitative RT-PCR, gene expression of cytokines and markers for T lymphocytes, monocytes/macrophages
and osteoclasts, respectively, was analysed in tissue samples obtained intraoperatively during exchange surgery of the
loosened implant. Peripheral T cells were characterized by cytofluorometry before surgery and 7 to 10 days thereafter.
Results: At sites of osteolysis, gene expression of cathepsin K, CD14 and CD3 was seen, indicating the generation of
osteoclasts, and the presence of monocytes and of T cells, respectively. Also cytokines were highly expressed, including
CXCL8, IL-1ß, CXCL2, MRP-14 and CXCL-10. The latter suggest T cell activation, a notion that could be confirmed by
detecting a small, though conspicuous population of activated CD4+ cells in the peripheral blood T cells prior to surgery.
Conclusion: Our data support the concept that metallosis is the result of a local inflammatory response, which according
to histomorphology and the composition of the cellular infiltrate classifies as an acute phase of a chronic inflammatory
disease. The proinflammatory environment, particularly the generation of the osteoclast-inducing cytokines CXCL8 and
IL1-ß, promotes bone resorption. Loss of bone results in implant loosening, which then causes the major symptoms of
metallosis, pain and reduced range of motion.
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In patients with osteoarthritis, replacement of dysfunctional
joints by endoprostheses is the therapy of choice. Particu-
larly total hip replacement is rated as the most successful
surgical intervention in the field of orthopaedics (reviewed
in [1]). An abundance of implants are available at the sur-
geons demand. Because of direct contact of the implanted
devices with tissues and serum mediator systems, materials
are designed to be biologically inert, and to allow the in-
growth of tissue cells, such as osteoblasts and fibroblasts
without eliciting adverse reactions from the patients.* Correspondence: Ulrike.Dapunt@med.uni-heidelberg.de
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unless otherwise stated.Unfortunately, implanted materials can release wear
particles which may elicit adverse reactions in patients,
apparent as localized inflammation with tissue damage
and bone degradation which finally results in loosening
of the implant (reviewed in [2]).
A special situation arises when so-called metal-on-metal
hip resurfacing implants are used. They have been intro-
duced especially for younger, active patients because healthy
bone is spared by this device (reviewed in [3,4]) (see also
Figure 1). Unfortunately, some metal-on-metal implants
release large amounts of wear particles, which are depos-
ited in the tissue and elicit adverse tissue reactions [5-12]
(see also Figure 1). This condition has been described
many years ago [13-15] and when patients experience severe
pain at the site of the implant and reduced range of motion,l Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain





Figure 1 Clinical and histological images. A Shown are x-rays of a patient with a metal-on-metal hip resurfacing implant (left) and on the right
of a patient with a total hip joint replacement. B After the removal of the implant, deposition of metal particles is seen as is the formation of a
pseudotumour (arrow). C The removed implants are shown; they are “empty” due to bone loss. D, E Biopsies from an osteolytic site show infiltration of
leukocytes, particularly of mononuclear cells, and deposits of metal wear particles.
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tools are not available, though elevated concentrations of
metal ions in the blood point towards an increased wear
[16]. Radiologic examination might reveal a deterioration
of bone around the implant, which could be responsible
for a loosening of the implant. A greyish coloring of the
tissue might be seen macroscopically when the implant is
removed.
Histology of tissue derived from patients with metallosis
shows a wide spectrum of changes. Areas of metal deposits
present with granulomatous inflammation, infiltrates of
monocytes and T cells, and occasionally giant cells. In
some patients tumour-like tissue formations, so-called
“pseudotumours”, are found in close proximity of the im-
plant, in others a perivascular accumulation of lympho-
cytes. [17-20]. The difference in morphology could reflect
different underlying pathomechanisms, for example distinct
responses to a higher versus a lower load of metal particles,
or alternatively, different stages of the disease [21,12].Basically, metallosis is thought to be the result of an
immune reaction to the metal wear particles. A participa-
tion of phagocytic cells is presumed, because they readily
take up particulate materials, and because they are activated
during that process to produce pro-inflammatory cytokines
(reviewed in [22]). A hypersensitivity towards metals in
form of a specific T cell mediated immune response has
also been suggested; a classical “type IV immune responses”
towards metal/metal ions, however, occurs only in a few
patients [23,24], leading to the notion that an allergic
reaction to metal ions is not a common denominator of
metallosis. Moreover, some studies failed to show typical
T cell activation markers or characteristic T cell-derived
cytokines [25]. However, due to their short half-life some
cytokines might escape detection by conventional methods,
and therefore a participation of T cells in the progression
of metal-induced tissue damage cannot be excluded. In the
present study we examined the local generation of cyto-
kines by gene expression analysis, particularly with regard
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degradation. Moreover, systemic T cell activation in patients
was assessed.
Patients, materials and methods
Patients
Five patients undergoing revision surgery due to a hip
resurfacing implant (metal-on-metal, ASR Hip System,
DePuy) and six patients suffering from aseptic loosening
of a total hip replacement (metal-on-polyethylene or
ceramic-on-polyethylene) were included in the study. Diag-
nosis of loosening was based on patient’s complaints, clin-
ical examination and by conventional x-ray and/or CT-scan
(patients’ clinical data are summarised in Table 1). The
study was approved by the local ethic committee, and
informed consent was obtained from the patients.
Collection of tissue and blood samples
During surgery, soft tissue samples were taken from the
cup, the capsule, the femur and for comparison from
muscle in a standardized fashion. The tissue samples were
divided, a part was fixed in formalin and conserved
for histological analysis, and another was placed intoTable 1 Patients’ clinical and laboratory findings ( metallosis
Patient Age Clinical signs Metal ions in peripheral blood
a) Chrome (>7 μg/L)
b) Cobalt (>7 μg/L)
Metallosis




2 47 Pain a) 17.7 μg/L
b) 38.90 μg/L
3 42 Pain a) 4.06 μg/L
b) 5.49 μg/L
4 71 Pain a) 15.0ug/L
b) 30.0ug/L
5 60 Non a) 43.0 μg/L
b) 64.0 μg/L
Patient Age Clinical signs
Aseptic loosening
1 70 Pain, osteolysis around cup and stem on x-ray
2 71 Pain, osteolysis around stem on x-ray
3 75 Pain, osteolysis around cup on x-ray
4 59 Pain, osteolysis around stem on x-ray
5 81 Pain, osteolysis around stem on x-ray
6 84 Pain, osteolysis around stem on x-ray
Metal ions were measured pre-operatively as indicator of increased wear debris.
CRP levels and white cell count were measured pre-operatively as signs of infectionRNAlater (Ambion, Lifetechnologies, Heidelberg, Germany)
for quantitative PCR analysis. Immediately before surgery,
and 7 to 10 days thereafter, peripheral blood was collected
into heparinized tubes and cells were subjected to cyto-
fluorometry (see below).
Histology
For routine histological evaluation, the samples were em-
bedded in paraffin, decalcified, and sections of 3 to 4 μM
were prepared for eosin-haematoxylin staining.
Gene expression analysis
The tissue samples were disrupted with RiboLyser devices
(ThermoHYBAID, Heidelberg, Germany) containing 400 μl
lysis buffer from the MagnaPure mRNA Isolation Kit con-
taining 1%DTT (v/w) (ROCHE Diagnostics, Mannheim,
Germany). mRNA was isolated with the MagnaPure-LC
device using the mRNA- standard protocol for cells. An
aliquot of mRNA was reversely transcribed using AMV-RT
and oligo- (dT) as primer (First Strand cDNA synthesis kit,
ROCHE Diagnostics, Mannheim, Germany) according to
the manufactures protocol in a thermocycler. Primer sets









2.3 mg/L 4.55/nl 8 Metal on metal
16.6 mg/L 8.96/nl 5 Metal on metal
3.6 mg/L 9.39/nl 6 Metal on metal
6.9 mg/L 5.89/nl 6 Metal on metal









17.3 mg/l 4.91/nl 19 Ceramic on polyethylene
10.0 mg/l 8.17/nl 3 Ceramic on polyethylene
2.0 mg/l 5.74/nl 15 Metal on polyethylene
2.0 mg/l 3.53/nl 2 Ceramic on polyethylene
2.0 mg/l 6.92/nl 12 Metal on polyethylene
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Figure 2 Expression of cathepsin K, CD14, CD3 and of
proinflammtory cytokines in tissue derived from the cup or
the muscle: cytokine expression was determined by RT-PCR
and quantified as number of transcripts. Data of 5 patients
(each symbol represent one patients) with metallosis are shown.
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LC.com). The PCR was performed with the LightCycler®
FastStart DNA Sybr GreenI kit (RAS) according to the
protocol provided. To control for specificity, a melting
curve analysis was performed. The copy number was
calculated from a standard curve, obtained by plotting
known input concentrations of four different plasmids
at log dilutions to the PCR-cycle number (CP) at which
the detected fluorescence intensity reaches a fixed value.
To correct for differences in the content of mRNA, the
calculated transcript numbers were normalized according
to the expression of the housekeeping gene peptidylprolyl
isomerase B (PPIB). Values were thus given as transcripts
per 1000 transcripts of PPIB.
Cytofluorometry
The following antibodies were used: CD4 PerCP, CD8
PerCP, CD11b PE, CD28 FITC (all Becton Dickinson,
Heidelberg, Germany), and the respective isotype: mouse
IgG1-PerCP, mouse IgG1-PE (all Becton Dickinson,
Heidelberg, Germany) and IgG1-FITC (Beckman Coulter,
Marseille, France). Whole heparinized blood (100 μl) was
incubated with the respective antibodies (20 min, room
temperature), erythrocytes were then lysed by Facs Lysing
solution and cells were washed and fixed with 1% para-
formaldehyde. Cells were analysed by FacsCalibur using
CellquestPro 3.0 as software (Becton and Dickinson,
Heidelberg, Germany).
Statistical analysis
Differences between groups were calculated using Fried-
man test and Mann–Whitney test, respectively (as indicated
in the figure legends or tables).
Results
Macroscopic and histological aspects of metallosis
Five patients with metallosis and six patients with aseptic
loosening were included in the study (patients’ data are
summarised in Table 1). The implant used in patients
developing metallosis is shown in Figure 1A. In compari-
son to other forms of endoprostheses, the femur is better
preserved, but because of the metal-on-metal contact,
metal wear particles accumulate at the site, macroscopic-
ally seen as greyish colouring (Figure 1B). In this example,
also pseudotumour formation occurred (Figure 1B), as did
osteolysis (Figure 1C). Biopsies taken from the site showed
metal wear particles, and also a cellular infiltrate, consist-
ing mainly of mononuclear cells (Figure 1D,E).
Gene expression of cathepsin K, CD3, CD14 and of
cytokines in tissue
Tissue samples from the cup and from the femoral bone
were taken from areas that were exposed after removal
of the implant. Moreover, samples from the capsule andwhen present from the pseudotumour, were gathered and
for comparison, from distant muscle as an unaffected site.
Gene expression of CD14 as marker for monocytes/mac-
rophages, of CD3 as marker for T cells and of cathepsin K,
characteristic for osteoclasts, was determined by quantita-
tive PCR. At the primary osteolytic site, the cup, expression
of cathepsin K, CD14 or CD3 was considerably higher
compared to expression in muscle (Figure 2). The absolute
numbers varied widely among the patients, but the expres-
sion pattern was similar.
In the same tissues, gene expression of proinflammatory
cytokines was analysed. CXCL8 (interleukin (IL)-8), IL-1ß,
CXCL2 (macrophage inflammatory protein, MIP2α) and
MRP14 (S100A9) were highly expressed in tissue of
the cup, again with a wide variation among the patients
(Table 2). Gene expression of TNFα (tumour necrosis factor
alpha), RANK (receptor activator of NfκB) or RANK ligand
(RANKL) was rather low in all tissues. The monocyte
chemotactic protein, MCP-1 (CCL2) was found in all
tissues with no apparent preference, as was CXCL10
(IP-10).
To address the question whether aspects of the cyto-
kine expression pattern were typical for metallosis, we
Table 2 Gene expression of cathepsin K, CD3, CD14 and
of cytokines in tissue of patients with metallosis
Parameter Cup Muscle Difference between
groups calculated by
Mann–Whitney test
Cathepsin K 2603.0 ± 1220.8* 968.4 ± 392.4 n.d.
CD3 288.6 ± 262.2 42.2 ± 26.4 p = 0.036
CD14 1806.2 ± 1211.9 334.2 ± 247.7 p = 0.012
CXCL8 677.0 ± 355.5 27.0 ± 20.8 p = 0.043
IL1ß 101.4 ± 90.7 9.0 ± 3.5 p = 0.043
CXCL2 276.5 ± 125.0 92.8 ± 51.5 p = 0.040
MRP14 82376.8 ± 78340.0 377.4 ± 396.0 p = 0.040
RANK 10.9 ± 9.8 8.2 ± 5.7 n.d.
RANKL 4.1 ± 4.0 0.2 ± 0.2 n.d.
TNFα 11.5 ± 4.0 7.3 ± 1.0 n.d.
CXCL10 184.7 ± 239.5 131.6 ± 147.8 n.d.
CCL2 1612.1 ± 1958.9 652.0 ± 144.8 n.d.
*copy number; n.d. = not different.
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requiring replacement of a hip implant because of aseptic
loosening.
Because for both patient groups tissue from the capsule
and from the femoral bone was available, gene expression
in these tissue were used, although these were not the
primary osteolytic sites, particularly not in patients with
metallosis. As summarised in Table 3, for metallosis pa-
tients essentially the same expression pattern was seen:
in tissue from either capsule or femoral bone, expression
of CXCL8, IL-1ß, CXCL2 and MRP14 was higher com-
pared to muscle tissue, as was expression of CD14. In
patients with aseptic loosening, in contrast, no majorTable 3 Cytokine expression in tissue of patients with metallo
Capsule
Metallosis Aseptic loosening Metallosis
CXCL8 1927.3 ± 328.4+ 106.2 ± 106.6 580 ± 316.2
IL-1 179.5 ± 293.5+ 11.2 ± 12.1 65 ± 44.7
RANK 5.6 ± 5.9 9.5 ± 8.8 11 ± 4.5
RANKL 4.4 ± 7 17.3 ± 18.7 11 ± 8.2
Cathepsin K 2708.8 ± 2139.7 4794.9 ± 2817.2 3313.3 ± 1646.1
CCL2 2005.7 ± 1321.5 990.7 ± 512.6 3439.8 ± 2892.6
CD14 1075.5 ± 659.1+ 563.2 ± 321+ 823.8 ± 488.9
CD3 64.1 ± 59.8 29.5 ± 15.7 111.5 ± 77.1
TNFα 10.6 ± 10 3.7 ± 2.2 12.8 ± 7
CXCL10 241.4 ± 246.2* 25.9 ± 17.6 183.8 ± 130*
MRP14 4899 ± 2656.3 * 806 ± 65 48214.3 ± 9161
CXCL2 241.2 ± 126.5 * 73.2 ± 59.2 670 ± 635.2
The bold print indicates that the groups differ significantly as tested by Mann–Whit
the + differences between capsule/femoral bone tissue and muscle.differences in cytokine expression were observed between
muscle and the other tissues; only CD14 was expressed to
a higher extent in femoral bone. In patients with metallo-
sis, CXCL8 and IL-1ß expression was higher by trend than
in patients with aseptic loosening; CXCL2 and CXCL10
were significantly higher expressed in patients with metal-
losis (Table 3).
Gene expression of CD3, CD14 and of the cytokines
was also determined in peripheral blood cells of the pa-
tients. No major differences were observed between
blood cells from patients with metallosis or with aseptic
loosening (data not shown). Only expression of CXCL10
was higher in blood cells of metallosis patient compared
to patients with aseptic loosening (9.4 ± 4.1 copies versus
1.7 ± 1.75).
Analysis of T cell response
Peripheral blood T cells were analysed for expression of
activation-associated receptors. As sensitive markers,
down-modulation of CD28 and up-regulation of CD11b
on CD4+ and CD8+ T cells was measured (example in
Figure 3A). Because the percentage of CD4 + CD28- and
CD8 +CD28- cells varies greatly among donors (mean ±
SD of n = 18: 6.51 ± 5.59% CD4 + CD28- and 37.4 ± 20.3%
CD8 + CD28-) [26], and because the activation of T
cells is transient, we determined the T cell population
in the patients immediately before surgery and 7 to
10 days thereafter. There were no major differences re-
garding CD8 + CD28- cells, whereas CD4 + CD28- cells
were seen in patients with metallosis (and not in patients
with aseptic loosening) (Figure 3B). CD11b upregulation
occurred in both, CD4+ and CD8+, and the percentage
declined after surgery, as did the mean values of CD11b
(Figure 3C).sis versus aseptic loosening
Femoral Muscle
Aseptic loosening Metallosis Aseptic loosening
379.2 ± 494.1 27 ± 20.8+ 181.3 ± 305.4
47.9 ± 48.4 9 ± 3.5+ 12.2 ± 18.8
26.3 ± 32.7 8.2 ± 5.7 19.3 ± 22.9
44.7 ± 50.2 0.2 ± 0.4 2 ± 4.9
6871.6 ± 4937.7 968.4 ± 392.4 2958.5 ± 3390.7
1196.3 ± 575.3 652 ± 144.8 1065.8 ± 1030.5
687.8 ± 417.2 288.8 ± 151.3 + 305.2 ± 175 +
62.2 ± 69.9 42.2 ± 26.5 45.7 ± 19.3
5.7 ± 3.7 5.8 ± 3.3 4.2 ± 6.2
41.7 ± 26.9 * 131.6 ± 147.8 607.2 ± 1167.8
7.3* 2461.3 ± 2529.1 377.4 ± 396 2186.7 ± 2080.3
133.8 ± 100.2 92.8 ± 51.6 262.3 ± 467.9
ney test; * indicates differences between metallosis and aseptic loosening;
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Figure 3 (See legend on next page.)
Dapunt et al. Journal of Translational Medicine 2014, 12:74 Page 6 of 9
http://www.translational-medicine.com/content/12/1/74
(See figure on previous page.)
Figure 3 Cytofluorometry of peripheral T cells. A By cytofluorometry the peripheral T cells of a patient before and 9 days after surgery were
analysed. Before surgery, 57.0% of CD8+ cells were negative for CD28, but only 45.6% after surgery; and 7.4% of CD4 versus 4.6% after surgery.
The CD8 + CD28- and CD4 + CD28- cells expressed CD11b, indicative of an activated T effector cell. B Shown is the percentage of CD4 + CD28- cells in
patients with metallosis (left) or patients with aseptic loosening (right) before and after surgery. C The mean fluorescence intensity of CD11b on T cells
declined after surgery (shown are data of four patients; each symbol refers to one patient and data obtained before and after surgery are connected
by a line).
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To get insights into the local immune response in patients
with metal-on-metal implants, tissue derived from osteolytic
sites was explored with regard to infiltrating leukocytes, gen-
eration of osteoclasts and production of pro-inflammatory
cytokines by gene expression analysis. High expression
of CD14 and of CD3 indicative of monocyte and T cell
infiltration was seen, as was expression of cathepsin K,
an enzyme typically expressed by osteoclasts. In osteolytic
tissue also genes encoding for pro-inflammatory cyto-
kines, including CXCL8, IL-1ß, CXCL2 and MRP14 were
highly expressed, reflecting a localized inflammatory re-
sponse. Expectedly, the number of gene transcripts varied
widely among the patients, reflecting the fact that most
likely multiple factors contribute to metallosis, such as the
abundance and size of the wear particles; the exposure
time of the local cells to wear particles; and also host-
inherent factors, particularly the responsiveness of leu-
kocytes to irritants, and their capacity to synthesize and
release cytokines.
With regard to osteolysis, gene expression of CXCL8,
IL-1ß and CXCL2 are of special interest. These are all
multifunctional cytokines that can promote the inflamma-
tory response, for example by attracting and activating
more leukocytes. Moreover, CXCL8, IL-1ß and CXCL2
can induce the generation of osteoclasts from precursor
cells, either directly or in combination with other cytokines
[27-29]. The high expression of these cytokines could ex-
plain that osteolysis occurs despite our finding that RANK
and RANKL, which are described as crucial in induction of
osteoclastogenesis in other conditions, are only marginally
expressed [30-32].
In patients with metallosis gene expression of cytokines,
particularly of CXCL2 and CXCL10, was higher compared
to patients with aseptic loosening of a total joint replace-
ment. Due to the small number of patients and the wide
variation among the patients the data have to be inter-
preted with caution. Possibly, metal wear particles elicit a
more prominent inflammation than wear particles derived
from metal-on-polyethylene or ceramic-on-polyethylene
implants. This explanation is supported by the fact that
in the latter implants, expression of most cytokines at
osteolytic sites did not exceed that in muscle. A quali-
tative different inflammatory response, however, cannot
be ruled out.The most likely source for CXCL8, CXCL2, IL-1ß and
MRP-14 are phagocytic cells, particularly infiltrated
monocytes, which – according to the literature – are
activated by wear particles. Monocyte infiltration as deter-
mined by CD14 gene expression was higher in patients
with metallosis, and to some extent reflects an activation
on monocytes, because it is known to be associated with
enhanced CD14 synthesis [33]. Whether monocyte activa-
tion by metal-on-metal implants differs in principle from
metal-on-polyethylene or ceramic-on-polyethylene implants
or whether it is only a quantitative difference cannot be
decided as yet, nor can we deduce from our data whether
this contributes to the lower cytokine expression in patients
with aseptic loosening.
CXCL8 and CXCL2 are also chemotactic for T cell sub-
populations [34-36] and T cell infiltrates were also seen in
patients with metallosis. Infiltration indicates an activation
of T cells; as typical T cell-derived cytokine interferon
gamma was indirectly assessed by determining CXCL10.
In the tissue, expression varied widely among the patients
with a trend towards higher expression in patients with
metallosis compared to patients with aseptic loosening.
CXCL10 was also found in peripheral blood T cells of
patients with metallosis, but not in the blood of patients
with aseptic loosening. Although the number of transcripts
was rather low, the data point to an activation of T cells in
metallosis. The interpretation is supported by the presence
of CD4+ and CD8+ cells which were CD28 negative
and expressed CD11b, a phenotype corresponding to
an activated effector cell [26,37]. The percentage of
CD4 + CD28- cells declined within days after removal
of the implant, as did the percentage of CD4+ or CD8+
cells expressing CD11b. Because CD8 + CD28- are long-
lived and remain longer in the circulation, the population
of CD8 +CD28- did not change as convincingly as CD4 +
CD28-.
The presence of activated effectors in the peripheral
blood and the decline following removal of the implant
is compatible with the presumption that the T cells are
activated in metallosis patients, but not in patients
with aseptic loosening. Systemic activation of T cells
could be a prerequisite for their emigration from the
blood vessel into an inflammatory site. The perivascular
accumulation of lymphocytes [20,21] as it is described in
patients with metallosis as “ALVAL” (aseptic lymphocytic
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trafficking.
How a systemic T cell activation occurs is still under
investigation. A specific immune response to metal ions
in terms of a type IV hypersensitivity is not regularly seen
in metallosis patients [23,24,38]. Possibly, metal-loaded
monocytes or macrophages emigrate to the lymph nodes
encountering T cells there, and activate the cells by a not
yet defined mechanism. Alternatively, metal ions in the
blood could affect T cells and T cell function, as it has
already been reported for tissue cells [39,40].
Conclusion
In conclusion, we consider metallosis as a clinical entity,
caused by a local inflammatory response, which according
to histomorphology and the composition of the cellular
infiltrate classifies as an acute phase of chronic inflamma-
tory disease. The inflammation persists because of the con-
stant triggering wear particles, which are released from the
implant over time, and possibly also by self-perpetuating
cytokine-driven processes. The proinflammatory environ-
ment favors the generation of bone resorbing cells; loss of
bone ensues in implant loosening, which then causes the
major symptoms of metallosis: pain and a reduced range
of motion.
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